[P-16] Characterisation of genomic alteration of FGFR3 by integrating analysis of the Cancer Genome Atlas
Mutations and fusions of the fibroblast growth factor receptor (FGFR) gene family occur in various cancer types. Recently erdafitinib has been approved by the FDA for the treatment of FGFR3-altered urothelial cancer. We performed an integrated analysis of the TCGA-pancancer atlas including 32 cancer types (n = 10,953) to reveal the novel alteration of FGFR3....
Category :
Brief communications
Page :
1